264
Participants
Start Date
April 30, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
February 28, 2029
Pneumococcal conjugate vaccine
10-valent pneumococcal polysaccharide conjugate vaccine at a dosage of 2μg for each serotype polysaccharide for 1, 5, 6A, 7F, 9V, 14, 19A, 19F, 23F, and 4μg for serotype 6B, conjugated to a carrier protein (CRM197), polysorbate 20 and aluminium phosphate as an adjuvant. Administered as an intramuscular injection of 0.5mL.
Typhoid conjugate vaccine
Typhoid conjugate vaccine at a dosage of 25μg purified Vi capsular polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid with preservative (2-Phenoxyethanol). Administered as an intramuscular injection of 0.5mL.
Guido Valadares National Hospital (HNGV), Dili
Collaborators (1)
Murdoch Childrens Research Institute
OTHER
The University of Western Australia
OTHER
University of Edinburgh
OTHER
Timor-Leste Ministry of Health
UNKNOWN
Nick Fancourt
OTHER